Evidence map›Paper›PMID 26474487›Full record

ArticlePloS one2015

Mouse Invariant Monoclonal Antibody NKT14: A Novel Tool to Manipulate iNKT Cell Function In Vivo.

Felix Scheuplein, Deanna J Lamont, Matthew E Poynter, Jonathan E Boyson, David Serreze, Lennart K A Lundblad, Robert Mashal, Robert Schaub

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Felix ScheupleinNKT Therapeutics, Inc., Waltham, MA, United States of America.
Deanna J LamontThe Jackson Laboratory, Bar Harbor, ME, United States of America.
Matthew E PoynterThe University of Vermont, Department of Medicine, Burlington, VT, United States of America.
Jonathan E BoysonThe University of Vermont, Department of Medicine, Burlington, VT, United States of America.
David SerrezeThe Jackson Laboratory, Bar Harbor, ME, United States of America.
Lennart K A LundbladThe University of Vermont, Department of Medicine, Burlington, VT, United States of America.
Robert MashalNKT Therapeutics, Inc., Waltham, MA, United States of America.
Robert SchaubNKT Therapeutics, Inc., Waltham, MA, United States of America.
NKT Therapeutics (United States) · USUniversity of Vermont · USJackson Laboratory · US

Funding

Shared Resource ManagementP30CA034196 · NCI · JACKSON LABORATORY · PI William Carl Skarnes · 1985 to 2026
$61.9M
Diabetogenic Role of MHC Class I Alleles in NOD MiceR01DK046266 · NIDDK · JACKSON LABORATORY · PI SERREZE, DAVID V · 2000 to 2018
$7.2M
B-lymphocyte Targeting Therapies for Autoimmune DiabetesR01DK095735 · NIDDK · JACKSON LABORATORY · PI SERREZE, DAVID V · 2013 to 2025
$6.2M
TRANSLATIONAL RESEARCH IN LUNG BIOLOGY AND DISEASEP30RR031158 · NCRR · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI IRVIN, CHARLES G · 2010 to 2011
$2.6M
A host genetic locus that regulates susceptibility to influenza infection.R21AI119974 · NIAID · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI BOYSON, JONATHAN E · 2015 to 2016
$423k
iNKT Cells Regulating Lung Mast Cells: New Treatment Opportunity for AsthmaR21AI112804 · NIAID · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI LUNDBLAD, LENNART KARL ALF · 2014 to 2015
$419k
NCI NIH HHS P30 CA034196NCRR NIH HHS P30 RR031158NIAID NIH HHS 1R21AI112804-01NIAID NIH HHS R21 AI112804NIAID NIH HHS R21 AI119974NIDDK NIH HHS R01 DK046266NIDDK NIH HHS R01 DK095735
6 · The paper itself

Abstract

Invariant Natural Killer T (iNKT) cells are a T cell subset expressing an invariant T Cell Receptor (TCR) that recognizes glycolipid antigens rather than peptides. The cells have both innate-like rapid cytokine release, and adaptive-like thymic positive selection. iNKT cell activation has been implicated in the pathogenesis of allergic asthma and inflammatory diseases, while reduced iNKT cell activation promotes infectious disease, cancer and certain autoimmune diseases such as Type 1 diabetes (T1D). Therapeutic means to reduce or deplete iNKT cells could treat inflammatory diseases, while approaches to promote their activation may have potential in certain infectious diseases, cancer or autoimmunity. Thus, we developed invariant TCR-specific monoclonal antibodies to better understand the role of iNKT cells in disease. We report here the first monoclonal antibodies specific for the mouse invariant TCR that by modifying the Fc construct can specifically deplete or activate iNKT cells in vivo in otherwise fully immuno-competent animals. We have used both the depleting and activating version of the antibody in the NOD model of T1D. As demonstrated previously using genetically iNKT cell deficient NOD mice, and in studies of glycolipid antigen activated iNKT cells in standard NOD mice, we found that antibody mediated depletion or activation of iNKT cells respectively accelerated and retarded T1D onset. In BALB/c mice, ovalbumin (OVA) mediated airway hyper-reactivity (AHR) was abrogated with iNKT cell depletion prior to OVA sensitization, confirming studies in knockout mice. Depletion of iNKT cells after sensitization had no effect on AHR in the conducting airways but did reduce AHR in the lung periphery. This result raises caution in the interpretation of studies that use animals that are genetically iNKT cell deficient from birth. These activating and depleting antibodies provide a novel tool to assess the therapeutic potential of iNKT cell manipulation.

Indexed as

AnimalsAntibodies, Monoclonal, Murine-DerivedAsthmaDiabetes Mellitus, Type 1Lymphocyte DepletionMiceMice, Inbred BALB CMice, Inbred NODNatural Killer T-CellsReceptors, Antigen, T-CellAntibodies, Monoclonal, Murine-DerivedReceptors, Antigen, T-Cell

Identifiers

PMID26474487
PMCPMC4608835
OpenAlexW2200270650

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.